Increasingly, medical researchers are identifying connections between systemic mastocytosis (SM), a rare disorder characterized by the abnormal accumulation of mast cells and disruptions in sleep, including insomnia. Whereas traditionally understood for its impact on skin, bone marrow, and the gastrointestinal tract, emerging evidence points to a more systemic effect, with kidney involvement and subsequent sleep disturbances becoming increasingly recognized.
Systemic mastocytosis arises from a gain-of-function mutation, often in the KIT gene, which prevents the programmed cell death of mast cells. These cells, crucial in allergic and inflammatory responses, release mediators like histamine, tryptase, and prostaglandins. The resulting multi-organ symptoms can include flushing, hives, fainting, bone pain, and diarrhea. However, the impact extends beyond these commonly recognized manifestations.
Kidney involvement, though infrequent as a direct result of SM, is being reported with greater frequency. Research indicates indirect kidney involvement, manifesting as monoclonal deposition disease, primary light chain amyloidosis, and immune-mediated glomerulonephritis, including mesangioproliferative glomerulonephritis, membranous nephropathy, and diffuse proliferative glomerulonephritis. Novel anti-neoplastic agents used to treat advanced SM, specifically tyrosine kinase inhibitors, have been associated with kidney dysfunction in some patients.
The link between kidney issues and sleep disorders is well-established. Studies show a significant prevalence of insomnia among patients with complete-stage kidney disease, ranging from 19 to 71 percent of those undergoing hemodialysis or peritoneal dialysis. Chronic kidney disease, in general, is associated with a range of sleep disturbances, including sleep apnea syndrome, restless legs syndrome, and periodic limb movement disorder. The precise mechanisms connecting SM-related kidney involvement to sleep disruption are still under investigation, but the correlation is becoming clearer.
The growing body of research highlights the require for clinicians to consider systemic mastocytosis in patients presenting with unexplained sleep disorders, particularly those with concurrent kidney issues. A narrative review published recently emphasizes the various ways kidneys and the urinary tract are involved in patients with SM, urging further investigation into the complex interplay between these conditions.
